bile duct cancer
The researchers hope to improve the genetic understanding of understudied populations with multiple myeloma, colorectal cancer, and bile duct cancer.
TCR2 Therapeutics, BMS to Study Gavo-Cel, Opdivo, Yervoy Combos in Mesothelin-Expressing Cancers
The Phase II study will evaluate various combinations of the immunotherapies in patients with NSCLC, ovarian cancer, bile duct cancer, and mesothelioma.
NICE Recommends Incyte's Pemazyre for FGFR2-Positive Bile Duct Cancer
The drug was approved in the UK for previously treated patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.
Chinese Regulators Accept Innovent's New Drug Application for Pemazyre
Innovent is seeking approval for pemigatinib for patients with previously treated cholangiocarcinoma with a FGFR2 fusion or rearrangement.
FDA Approves Bile Duct Cancer Drug from Helsinn, BridgeBio Pharma With Foundation Medicine CDx
Truseltiq is a new option for FGFR2 fusion-positive, locally advanced, or metastatic cholangiocarcinoma patients who have received prior treatment.